Antitumor activity of sulfated hyaluronic acid fragments in pre-clinical models of bladder cancer

Andre R. Jordan, Soum D. Lokeshwar, Luis E. Lopez, Martin Hennig, Juan Chipollini, Travis Yates, Marie C. Hupe, Axel S. Merseburger, Aviva Shiedlin, Wolfgang H. Cerwinka, Kebin Liu, Vinata B. Lokeshwar

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Tumor cell-derived hyaluronidase HYAL-1 degrades hyaluronic acid (HA) into angiogenic fragments (AGF: 10-12 disaccharides). AGF support tumor growth and progression. Urine and tissue HAase/HYAL-1 levels are sensitive markers for highgrade bladder cancer (BCa) and its metastasis. In preclinical models of BCa, we evaluated whether o-sulfated AGF (sHA-F) inhibits HAase activity and has antitumor activity. At IC 50 for HAase activity inhibition (5-20 μg/ml [0.4-1.7 μM]), sHA-F significantly inhibited proliferation, motility and invasion of HYAL-1 expressing BCa cells (253J-Lung, HT1376, UMUC-3), P < 0.001. sHA-F did not affect the growth of HYAL-1 non-expressing BCa (5637, RT4, T24, TCCSUP) and normal urothelial (Urotsa, SV-HUC1) cells. sHA-F treatment induced apoptosis by death receptor pathway. sHA-F downregulated transcript and/or protein levels of HA receptors (CD44, RHAMM), p-AKT, β-catenin, pβ-Catenin(S552), Snail and Twist but increased levels of pβ- Catenin(T41/S45), pGSK-3α/β(S21/S9) and E-cadherin. sHA-F also inhibited CD44/ Phosphoinositide 3-kinase (PI-3K) complex formation and PI-3K activity. AGF addition or myristoylated-AKT overexpression attenuated sHA-F effects. Contrarily, HYAL- 1 expression sensitized RT4 cells to sHA-F treatment. In the 253J-L and HT1376 xenograft models, sHA-F treatment significantly inhibited tumor growth (P < 0.001), plausibly by inhibiting angiogenesis and HA receptor-PI-3K/AKT signaling. This study delineates that sHA-F targets tumor-associated HA-HAase system and could be potentially useful in BCa treatment.

Original languageEnglish (US)
Pages (from-to)24262-24274
Number of pages13
JournalOncotarget
Volume8
Issue number15
DOIs
StatePublished - Jan 1 2017

Fingerprint

Hyaluronic Acid
Urinary Bladder Neoplasms
Catenins
1-Phosphatidylinositol 4-Kinase
Neoplasms
Growth
Death Domain Receptors
Hyaluronoglucosaminidase
Disaccharides
Cadherins
Heterografts
Down-Regulation
Urine
Apoptosis
Neoplasm Metastasis
Lung
Proteins

Keywords

  • Bladder cancer
  • Hyaluronic acid
  • Hyaluronidase
  • Sulfated-HA
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology

Cite this

Jordan, A. R., Lokeshwar, S. D., Lopez, L. E., Hennig, M., Chipollini, J., Yates, T., ... Lokeshwar, V. B. (2017). Antitumor activity of sulfated hyaluronic acid fragments in pre-clinical models of bladder cancer. Oncotarget, 8(15), 24262-24274. https://doi.org/10.18632/oncotarget.10529

Antitumor activity of sulfated hyaluronic acid fragments in pre-clinical models of bladder cancer. / Jordan, Andre R.; Lokeshwar, Soum D.; Lopez, Luis E.; Hennig, Martin; Chipollini, Juan; Yates, Travis; Hupe, Marie C.; Merseburger, Axel S.; Shiedlin, Aviva; Cerwinka, Wolfgang H.; Liu, Kebin; Lokeshwar, Vinata B.

In: Oncotarget, Vol. 8, No. 15, 01.01.2017, p. 24262-24274.

Research output: Contribution to journalArticle

Jordan, AR, Lokeshwar, SD, Lopez, LE, Hennig, M, Chipollini, J, Yates, T, Hupe, MC, Merseburger, AS, Shiedlin, A, Cerwinka, WH, Liu, K & Lokeshwar, VB 2017, 'Antitumor activity of sulfated hyaluronic acid fragments in pre-clinical models of bladder cancer', Oncotarget, vol. 8, no. 15, pp. 24262-24274. https://doi.org/10.18632/oncotarget.10529
Jordan AR, Lokeshwar SD, Lopez LE, Hennig M, Chipollini J, Yates T et al. Antitumor activity of sulfated hyaluronic acid fragments in pre-clinical models of bladder cancer. Oncotarget. 2017 Jan 1;8(15):24262-24274. https://doi.org/10.18632/oncotarget.10529
Jordan, Andre R. ; Lokeshwar, Soum D. ; Lopez, Luis E. ; Hennig, Martin ; Chipollini, Juan ; Yates, Travis ; Hupe, Marie C. ; Merseburger, Axel S. ; Shiedlin, Aviva ; Cerwinka, Wolfgang H. ; Liu, Kebin ; Lokeshwar, Vinata B. / Antitumor activity of sulfated hyaluronic acid fragments in pre-clinical models of bladder cancer. In: Oncotarget. 2017 ; Vol. 8, No. 15. pp. 24262-24274.
@article{ba8ff98d56b54466b38a7962cd0bfad7,
title = "Antitumor activity of sulfated hyaluronic acid fragments in pre-clinical models of bladder cancer",
abstract = "Tumor cell-derived hyaluronidase HYAL-1 degrades hyaluronic acid (HA) into angiogenic fragments (AGF: 10-12 disaccharides). AGF support tumor growth and progression. Urine and tissue HAase/HYAL-1 levels are sensitive markers for highgrade bladder cancer (BCa) and its metastasis. In preclinical models of BCa, we evaluated whether o-sulfated AGF (sHA-F) inhibits HAase activity and has antitumor activity. At IC 50 for HAase activity inhibition (5-20 μg/ml [0.4-1.7 μM]), sHA-F significantly inhibited proliferation, motility and invasion of HYAL-1 expressing BCa cells (253J-Lung, HT1376, UMUC-3), P < 0.001. sHA-F did not affect the growth of HYAL-1 non-expressing BCa (5637, RT4, T24, TCCSUP) and normal urothelial (Urotsa, SV-HUC1) cells. sHA-F treatment induced apoptosis by death receptor pathway. sHA-F downregulated transcript and/or protein levels of HA receptors (CD44, RHAMM), p-AKT, β-catenin, pβ-Catenin(S552), Snail and Twist but increased levels of pβ- Catenin(T41/S45), pGSK-3α/β(S21/S9) and E-cadherin. sHA-F also inhibited CD44/ Phosphoinositide 3-kinase (PI-3K) complex formation and PI-3K activity. AGF addition or myristoylated-AKT overexpression attenuated sHA-F effects. Contrarily, HYAL- 1 expression sensitized RT4 cells to sHA-F treatment. In the 253J-L and HT1376 xenograft models, sHA-F treatment significantly inhibited tumor growth (P < 0.001), plausibly by inhibiting angiogenesis and HA receptor-PI-3K/AKT signaling. This study delineates that sHA-F targets tumor-associated HA-HAase system and could be potentially useful in BCa treatment.",
keywords = "Bladder cancer, Hyaluronic acid, Hyaluronidase, Sulfated-HA, Targeted therapy",
author = "Jordan, {Andre R.} and Lokeshwar, {Soum D.} and Lopez, {Luis E.} and Martin Hennig and Juan Chipollini and Travis Yates and Hupe, {Marie C.} and Merseburger, {Axel S.} and Aviva Shiedlin and Cerwinka, {Wolfgang H.} and Kebin Liu and Lokeshwar, {Vinata B.}",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.10529",
language = "English (US)",
volume = "8",
pages = "24262--24274",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "15",

}

TY - JOUR

T1 - Antitumor activity of sulfated hyaluronic acid fragments in pre-clinical models of bladder cancer

AU - Jordan, Andre R.

AU - Lokeshwar, Soum D.

AU - Lopez, Luis E.

AU - Hennig, Martin

AU - Chipollini, Juan

AU - Yates, Travis

AU - Hupe, Marie C.

AU - Merseburger, Axel S.

AU - Shiedlin, Aviva

AU - Cerwinka, Wolfgang H.

AU - Liu, Kebin

AU - Lokeshwar, Vinata B.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Tumor cell-derived hyaluronidase HYAL-1 degrades hyaluronic acid (HA) into angiogenic fragments (AGF: 10-12 disaccharides). AGF support tumor growth and progression. Urine and tissue HAase/HYAL-1 levels are sensitive markers for highgrade bladder cancer (BCa) and its metastasis. In preclinical models of BCa, we evaluated whether o-sulfated AGF (sHA-F) inhibits HAase activity and has antitumor activity. At IC 50 for HAase activity inhibition (5-20 μg/ml [0.4-1.7 μM]), sHA-F significantly inhibited proliferation, motility and invasion of HYAL-1 expressing BCa cells (253J-Lung, HT1376, UMUC-3), P < 0.001. sHA-F did not affect the growth of HYAL-1 non-expressing BCa (5637, RT4, T24, TCCSUP) and normal urothelial (Urotsa, SV-HUC1) cells. sHA-F treatment induced apoptosis by death receptor pathway. sHA-F downregulated transcript and/or protein levels of HA receptors (CD44, RHAMM), p-AKT, β-catenin, pβ-Catenin(S552), Snail and Twist but increased levels of pβ- Catenin(T41/S45), pGSK-3α/β(S21/S9) and E-cadherin. sHA-F also inhibited CD44/ Phosphoinositide 3-kinase (PI-3K) complex formation and PI-3K activity. AGF addition or myristoylated-AKT overexpression attenuated sHA-F effects. Contrarily, HYAL- 1 expression sensitized RT4 cells to sHA-F treatment. In the 253J-L and HT1376 xenograft models, sHA-F treatment significantly inhibited tumor growth (P < 0.001), plausibly by inhibiting angiogenesis and HA receptor-PI-3K/AKT signaling. This study delineates that sHA-F targets tumor-associated HA-HAase system and could be potentially useful in BCa treatment.

AB - Tumor cell-derived hyaluronidase HYAL-1 degrades hyaluronic acid (HA) into angiogenic fragments (AGF: 10-12 disaccharides). AGF support tumor growth and progression. Urine and tissue HAase/HYAL-1 levels are sensitive markers for highgrade bladder cancer (BCa) and its metastasis. In preclinical models of BCa, we evaluated whether o-sulfated AGF (sHA-F) inhibits HAase activity and has antitumor activity. At IC 50 for HAase activity inhibition (5-20 μg/ml [0.4-1.7 μM]), sHA-F significantly inhibited proliferation, motility and invasion of HYAL-1 expressing BCa cells (253J-Lung, HT1376, UMUC-3), P < 0.001. sHA-F did not affect the growth of HYAL-1 non-expressing BCa (5637, RT4, T24, TCCSUP) and normal urothelial (Urotsa, SV-HUC1) cells. sHA-F treatment induced apoptosis by death receptor pathway. sHA-F downregulated transcript and/or protein levels of HA receptors (CD44, RHAMM), p-AKT, β-catenin, pβ-Catenin(S552), Snail and Twist but increased levels of pβ- Catenin(T41/S45), pGSK-3α/β(S21/S9) and E-cadherin. sHA-F also inhibited CD44/ Phosphoinositide 3-kinase (PI-3K) complex formation and PI-3K activity. AGF addition or myristoylated-AKT overexpression attenuated sHA-F effects. Contrarily, HYAL- 1 expression sensitized RT4 cells to sHA-F treatment. In the 253J-L and HT1376 xenograft models, sHA-F treatment significantly inhibited tumor growth (P < 0.001), plausibly by inhibiting angiogenesis and HA receptor-PI-3K/AKT signaling. This study delineates that sHA-F targets tumor-associated HA-HAase system and could be potentially useful in BCa treatment.

KW - Bladder cancer

KW - Hyaluronic acid

KW - Hyaluronidase

KW - Sulfated-HA

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85017550155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017550155&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.10529

DO - 10.18632/oncotarget.10529

M3 - Article

AN - SCOPUS:85017550155

VL - 8

SP - 24262

EP - 24274

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 15

ER -